Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Prospective, Observational Study to Evaluate Blood Pressure Control Rates and Safety of Ex-one Tablet or Ex-one Plus Tablet in Patients With Essential Hypertension in Real-world Clinical Practice

NCT07930247 is registered in ClinicalTrials.gov with HK inno.N Corporation as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07930247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Prospective, Observational Study to Evaluate Blood Pressure Control Rates and Safety of Ex-one Tablet or Ex-one Plus Tablet in Patients With Essential Hypertension in Real-world Clinical Practice
Lead sponsor
HK inno.N Corporation
Phase
Observational
Overall status
Recruiting
Start date
May 21, 2026
Completion date
June 30, 2031
Enrollment
7,525 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Proportion of patients achieving blood pressure control rates at Week 24 after treatment with Ex-one tablets or Ex-one Plus tablets At Week 24 after enrollment

    Blood pressure treatment target of \<140/90 mmHg, according to the 2022 Guidelines for the Management of Hypertension issued by the Korean Society of Hypertension

Lead sponsor's other trials

HK inno.N Corporation, most recent start first.

Similar trials

Same condition (Essential Hypertension) and phase, most recent start first.